@Article{or.2024.054201,
AUTHOR = {JIAHENG WEI, LIANGMING ZHU},
TITLE = {The role of glutathione peroxidase 4 in the progression, drug resistance, and targeted therapy of non-small cell lung cancer},
JOURNAL = {Oncology Research},
VOLUME = {33},
YEAR = {2025},
NUMBER = {4},
PAGES = {863--872},
URL = {http://www.techscience.com/or/v33n4/60029},
ISSN = {1555-3906},
ABSTRACT = {Lung cancer is one of the main causes of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) being the most prevalent histological subtype of lung cancer. Glutathione peroxidase 4 (GPX4) is a crucial antioxidant enzyme that plays a role in regulating ferroptosis. It is also involved in a wide variety of biological processes, such as tumor cell growth invasion, migration, and resistance to drugs. This study comprehensively examined the role of GPX4 in NSCLC and investigated the clinical feasibility of targeting GPX4 for NSCLC treatment. We discovered that GPX4 influences the progression of NSCLC by modulating multiple signaling pathways, and that blocking GPX4 can trigger ferroptosis and increase the sensitivity to chemotherapy. As a result, GPX4 represents a prospective therapeutic target for NSCLC. Targeting GPX4 inhibits the development of NSCLC cells and decreases their resistance to treatment.},
DOI = {10.32604/or.2024.054201}
}